|
|
|
| Effect of Meropenem De-Escalation Therapy on Pulmonary Function and CPIS Score in Elderly Patients with Respiratory Failure Complicated by Pulmonary Infection |
| CUI Xiaoqing |
| Department of Pharmaceutical, Funing County People's Hospital, Yancheng Jiangsu 224400 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of meropenem de-escalation therapy on pulmonary function and clinical pulmonary infection score (CPIS) in elderly patients with respiratory failure complicated by pulmonary infection. 【Methods】 A total of 97 elderly patients with respiratory failure complicated by pulmonary infection admitted to our Hospital from August 2022 to August 2024 were enrolled. According to the treatment methods, they were divided into a conventional treatment group (n=48) and a meropenem group (n=49). The conventional group received standard antibiotic therapy, while the meropenem group was treated with meropenem de-escalation therapy. Clinical efficacy, pulmonary function, arterial blood gas parameters, Acute Physiology and Chronic Health Evaluation Ⅱ(APACHE Ⅱ) scores, CPIS scores, and biomarker levels were compared between the two groups. 【Results】 The treatment efficacy in the meropenem group was significantly higher than that in the conventional group (P<0.05). After treatment, the meropenem group showed significantly higher forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF) than the conventional group (P<0.05). Arterial oxygen partial pressure (PaO2) and oxygenation index (OI) were also higher in the meropenem group, while arterial carbon dioxide partial pressure (PaCO2) was lower (P<0.05). The APACHE Ⅱ and CPIS scores in the meropenem group were significantly lower than those in the conventional group (P<0.05). Additionally, serum levels of procalcitonin (PCT), pentraxin-3 (PTX3), and high mobility group box protein 1 (HMGB1) in the meropenem group were significantly lower than those in the conventional group (P<0.05). 【Conclusion】 Meropenem de-escalation therapy has a significant impact on improving pulmonary function and reducing CPIS scores in elderly patients with respiratory failure complicated by pulmonary infection.
|
|
Received: 03 December 2025
|
|
|
|
|
|
[1] CARRATALÁ J M, DIAZ-LOBATO S, BROUZET B, et al.Efficacy and safety of high-flow nasal cannula therapy in elderly patients with acute respiratory failure[J].Pulmonology,2024, 30(5): 437-444.
[2] CRISAFULLI E, SARTORI G, VIANELLO A, et al. Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both[J].Intern Emerg Med,2023, 18(2): 523-534.
[3] 徐震林,李奕鑫,赵国平,等. 利奈唑胺联合美罗培南对重症肺炎患者血气指标及血清膜联蛋白A1水平的影响[J].疑难病杂志,2025,24(3):318-322.
[4] 童仁香,常甄瑱,陈倩,等. 头孢哌酮舒巴坦钠联合美罗培南治疗细菌感染性重症肺炎患儿的临床疗效[J].川北医学院学报,2025,40(2):210-214.
[5] 刘星,陈利芬,杨数理,等. 美罗培南降阶梯治疗对老年呼吸衰竭合并肺部感染的疗效[J].中华医院感染学杂志,2024,34(22):3382-3386.
[6] 张维维,杨艳,吴可人,等. 美罗培南降阶梯疗法对老年慢性阻塞性肺疾病合并肺炎患者的效果[J].中国医药导报,2023,20(7):110-113.
[7] 葛均波,徐永健,王辰.内科学[M].9版.北京:人民卫生出版社,2018:41-57.
[8] 卫生部.国家中医药管理局,总后卫生部.抗菌药物临床应用指导原则[J].中国中医药现代远程教育,2004,2(11):10-11.
[9] 张鸥,周祥林,吴萍,等. 血清NGAL水平联合APACHEⅡ评分对重症肺炎并发急性肾损伤患者预后的预测价值[J].广西医学,2024,46(4):495-500.
[10] 高海波,郭翠翠,张俊霞,等. 重症肺炎胸部CT表现联合CPIS评分对预后的评估价值分析[J].中国CT和MRI杂志,2024,22(12):64-66.
[11] BRUNKER L B, BONCYK C S, RENGEL K F, et al. Elderly patients and management in intensive care units (ICU): clinical challenges[J].Clin Interv Aging,2023,18:93-112.
[12] 王文娟,路佩源,杨晓彤,等. 美罗培南基于TDM个体化治疗重症感染患者的研究应用[J].中国临床药理学与治疗学,2024,29(12):1329-1336.
[13] 朱洋,顾慧,李建如,等. 重症肺部感染患者应用乙酰半胱氨酸雾化联合美罗培南的效果分析[J].河北医药,2024,46(20):3139-3141.
[14] 黄振,刘乃嘉. 血乳酸联合APACHE Ⅱ评分预测慢性阻塞性肺疾病急性加重期并呼吸衰竭预后的价值[J].局解手术学杂志,2023,32(9):795-799.
[15] 张慧. 基于CPIS评分护理干预预防脑卒中肺部感染的研究[J].现代中西医结合杂志,2023,32(10):1427-1430. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(2): 350-353. |
|
|
|
|
2026, Vol. 43 
